INSMED (IM8N BE) stock market data APIs
€142.871
0(0%)
as of October 21, 2025
Try our APIs with
free plan!
INSMED Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for IM8N.BE.
Prev. Close
142.871
Open
142.871
High
142.871
Low
142.871
52 wk Range
55-143
Market Cap
2 766 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INSMED data using free add-ons & libraries
Get INSMED Fundamental Data
INSMED Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INSMED News
New
Should Insmed’s (INSM) EMA Nod for BRINSUPRI Prompt a Fresh Look at Its Growth Prospects?
On October 17, 2025, Insmed announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of BRINSUPRI for non-cystic...
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic Inflam...
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker— —Additional Analyses Will Highlight Efficacy, Symptom Reduction, and Biomarker Suppression i...
Does Insmed Incorporated (INSM) Have a Promising Pipeline?
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets conti...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
